how many people on glp 1 Opportunities for nutrition brands in the GLP-1 boom Dangers of Taking GLP‑1 in

Weve been trying to bust that stigma a lot of years, Fitch told CNN

Notably, nearly 50% of the retatrutide phase 2 obesity trial were men, which is higher than in phase 3 clinical trials with tirzepatide (32.5% in SURMOUNT-1 [27]) and semaglutide 2.4 mg (25.9% in STEP-1 [8])

Implement remote patient management tools like symptom trackers and wearables (e.g., smart scales) for continuous monitoring and improved patient outcomes

In the lawsuit against Novo Nordisk regarding Ozempic, the main complaint is that the company didnt properly warn doctors and patients about the risk of gastroparesis, a serious stomach condition, when taking the drug